Remove 2020 Remove FDA Remove Packaging
article thumbnail

Common pharma compliance concerns cited by FDA warning letters

European Pharmaceutical Review

A study of the causes of warning letters issued by the US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) and Center for Devices and Radiological Health (CDRH) between 2010 and 2020 revealed that poor current good manufacturing practice (cGMP) compliance and misbranding were the most common citations.

FDA 105
article thumbnail

FDA releases draft guidance for decentralised clinical trials

European Pharmaceutical Review

The US Food and Drug Administration (FDA) has released a new draft guidance to further support the use of decentralised clinical trials (DCTs) for drugs, biologics and devices. This draft guidance builds on recommendations published by the agency in 2020.

FDA 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Rising Demand for Pharmaceutical Secondary Packaging Providers

Roots Analysis

On an average, around 50 drugs are approved by the US Food and Drug Administration (US FDA) annually. This continuously growing pipeline of pharmaceutical drug products has inadvertently led to an increase in the demand for their associated primary packaging and Secondary Packaging solutions. . trillion in 2023.

article thumbnail

Exclusive interview with ForwardVue Pharma released for Ophthalmic Drugs 2020

pharmaphorum

The NDA for Abicipar pegol, which utilizes DARPin technology was rejected by the FDA secondary to concerns of inflammation with the 2 mg dose”. What current topic will you be addressing in your presentation, and what would you say makes it relevant to 2020? “We 23 rd -24 th November 2020. Ophthalmic Drugs Conference.

article thumbnail

Mastering Responses to FDA 510(k) AI Letters: A Strategic Approach

The FDA Law Blog

After a firm submits a 510(k) to FDA, FDA will request still more information after a first-pass review. According to the 2 nd Quarter FY2023 MDUFA V Performance Report , FDA issued a request for additional information (AI request) on the first FDA review cycle for 63% to 68% of 510(k)s submitted in FY2018 to FY2022.

FDA 75
article thumbnail

What FDA’s Newest Gene Therapy Approval Tells Us About Durability: How Long is Long Enough?

The FDA Law Blog

Valentine — On November 22, 2022, FDA approved CSL Behring’s BLA for Hemgenix (etranacogene dezaparvovec), an AAV-based gene therapy for the treatment of adults with Hemophilia B who currently use Factor IX prophylaxis therapy, have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.

FDA 119
article thumbnail

Lilly injects $450m into plant making Mounjaro

pharmaphorum

billion since 2020. It will boost the site’s its capacity for parenteral filling, device assembly and packaging even further. The plant in Research Triangle Park has already received hefty investment from Lilly, and the new tranche will take the tally to $1.7